Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and Tremelimumab with or without SIRT for Resectable Hepatocellular Carcinoma
NCT05701488Phase 1Active, not recruiting
- Start
- Apr 2023
- Primary completion
- Oct 2026
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of durvalumab and tremelimumab in hepatocellular carcinoma (HCC) (2 arms). Primary endpoint: Number of Participants with Adverse Events at 18 months. Started Apr 2023; status: active, not recruiting.
02
Drugs
durvalumabtremelimumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05701488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05701488.